44 results about "Glutamate oxaloacetate transaminase" patented technology

The invention relates to a model and a system for predicting severe new coronal pneumonia as well as an establishment method and a prediction method of the model and the system, and the prediction model is a progression risk score calculation model obtained according to lung diseases, age, immune globulin M (IgM), CD16 +/CD56 + NK cells and aspartate transaminase (AST) of a patient with new coronal pneumonia so as to predict the risk of progressing from mild/ordinary type to severe new coronal pneumonia. According to the invention, light/ordinary patients with high development risk can be identified, and the diagnosis and treatment success rate of critical patients can be improved.

The invention discloses a preparation method and an application of Thais clavigera Kuster polysaccharide. The method comprises the following steps: taking fresh Thais clavigera Kuster as an initial material, boiling with water, removing shells, taking meat, carrying out vacuum freeze drying treatment, and carrying out alkaline water extraction, ethanol precipitation, protease enzymolysis, macroporous resin decolorization and ultrafiltration to obtain the refined polysaccharide component of which proteins and pigments are removed and the molecular weight is greater than 10 kD. The Thais clavigera Kuster polysaccharide prepared in the invention has remarkable anti-hepatitis B activity, can remarkably reduce the content of glutamic-pyruvic transaminase (ALT) and glutamic oxalacetic transaminase (AST) in serum, and plays a great role in protecting the liver.

The invention belongs to the technical field of aquaculture, and particularly relates to a low-protein feed for improving growth performance of litopenaeus vannamei and application thereof. The low-protein feed comprise nucleotide, and is used for improving the digestion and absorption capacity of the litopenaeus vannamei to nutrient substances in feed, improving growth performance of the litopenaeus vannamei, improving the body composition and serum biochemical indexes of the litopenaeus vannamei and improving immunity of the litopenaeus vannamei. The nucleotide comprises 5'-cytidylate, 5'-adenylate, disodium 5'-inosinate, disodium 5'-uridylate, disodium 5'-guanylate and disodium 5'-thymidylate. The low-protein feed of the present invention is mainly used for improving crude fat content,serum glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, hepatopancreatic glutamic-pyruvic transaminase, blood cell count, serum PO activity and the total protein content in stomachsand intestinal tracts of the litopenaeus vannamei.

The invention discloses an oplopanaxelatusNakai chlorogenic acid extract and a preparation method and application thereof. The method comprises the steps that an adventitious root material of oplopanaxelatusNakai is obtained by combining a tissue culture means and utilizing a bioreactor, and the chlorogenic acid extract of oplopanaxelatusNakai is obtained through macroporous adsorption resin extraction and separation. The adventitious root chlorogenic acid extract of oplopanaxelatusNakai can significantly protect liver injury caused by acetaminophen, the liver necrosis degree is obviously reduced, the levels of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase can be significantly reduced, mitochondrial oxidative stress reaction caused by liver injury caused by excessive acetaminophen can be reduced, the activity of superoxide dismutase, catalase and glutathione in the liver is obviously restored, the content of malondialdehyde is reduced, the drug metabolism of acetaminophen in the liver is affected, and therefore the aseptic inflammatory injury of neutral granulocytes to the liver is reduced, the liver is protected, and liver injury is reduced.

The invention relates to application of gentiopicroside in preparation of medicines for treating non-alcoholic fatty liver diseases. Experiments prove that the gentiopicroside can achieve the following effects in non-alcoholic fatty liver diseases caused by fructose: obviously limiting increase of mouse weight and decrease of food ration, lowering triglycerides (TG), uric acid (UA) and glucose (GLU) as well as levels of serum glutamic oxalacetic transaminase (AST) and glutamic-pyruvic transaminase (ALT), obviously alleviating vacuolar degeneration of hepatic cells and deposition of fatty acidscaused by fructose, lowering levels of tumor necrosis factors (TNF-alpha) and interleukin 6 (IL-6) in hepatic tissues, raising levels of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px)in the hepatic tissues and lowering levels of malondialdehyde (MDA) and superoxide anions (O2<->). Results show that the gentiopicroside can achieve the effects of obviously promoting metabolism of the liver on fat, obviously improving and increasing the antioxidant stress level of the liver and alleviating hepatocellular injury, so that the aim of treating the fatty liver diseases is achieved.

The invention discloses a preparation method of earthworm powder. The preparation method includes the following steps: cleaning and disinfecting earthworms, and performing homogenization and freezing;performing re-homogenization and re-freezing after thawing; and performing vacuum freeze-drying on the re-frozen homogenate so as to prepare the earthworm powder. The prepared earthworm powder can significantly reduce the levels of total cholesterol, triglyceride and low-density lipoprotein cholesterol in patients with hyperlipidemia and can also reduce the level of glutamic oxaloacetic transaminase and glutamic-pyruvic transaminase to normal level without affecting liver functions; and the earthworm powder can improve blood viscosity, and finally, the situations of blood supply of body tissue can be improved so as to make blood vessels healthier.

The invention provides a Chinese patent medicine for treating rise of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase and a preparation method of the Chinese patent medicine. The Chinese patent medicine comprises the following components in parts by weight: 500-2000 parts of radix sophorae flavescentis, 500-1000 parts of lysimachia christinae hance, 500-1000 parts of talc, 200-500 parts of liquorice, 500-1000 parts of plantain herb and 300-1000 parts of salviae miltiorrhizae. The Chinese patent medicine for treating rise of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase provided by the invention can quickly discharge intrahepatic damp and heat, so that the liver function can get right within a short time. The Chinese patent medicine for treating rise of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase provided by the invention is fast to take effect, good in curative effect and less in toxic and side effects to a human body.

The invention relates to application of ginsenoside Rg1 to preparation of a bilirubin rising treating preparation. In a single drinking experiment, the Rg1 can obviously reduce the content of triglyceride in blood; in a heavy drinking model, the Rg1 can obviously improve the survival rate of a drinking mice, reduces the content of glutamic pyruvic transaminase and glutamic oxalacetic transaminase in blood serum, reduces the content of cholesterol, the triglyceride and bilirubin in blood, and the like.

The invention discloses a new medicinal application of a Naoxintong preparation, and particularly relates to an application of the Naoxintong preparation in preparation of a medicine for treating non-alcoholic fatty liver. Experiments prove that the Naoxintong preparation can significantly reduce the body weight, liver weight/body weight index and liver lipid deposition of non-alcoholic fatty liver model animals, significantly improve liver function indexes including aspartate transaminase (AST) and glutamic-pyruvic transaminase (ALT), significantly reduce the levels of triglyceride (TG), cholesterol (TC) and low density lipoprotein (LDL-C) in serum in vivo, and significantly improve the liver function indexes of non-alcoholic fatty liver model animals. The traditional Chinese medicine composition has a remarkable effect on treating the non-alcoholic fatty liver disease. The medicinal range of the Naoxintong preparation is further expanded.

The invention provides application of a compound shown in a formula I in preparation of a drug for treating obesity and obesity-related symptoms, wherein R1, R2 and R3 are the same or different and are respectively selected from halogen elements; R4 is substituted or unsubstituted C1-C10 straight-chain or branched-chain alkyl; and R5 is a basic group. The research shows that the compound shown inthe formula I can effectively reduce the weight of high-fat diet-induced obese mice, OB mice and db/db mice, reduce the activity of glutamic-pyruvic transaminase ALT and glutamic oxalacetic transaminase AST and improve the fatty liver symptom. Therefore, the compound shown in the formula I has an improvement effect on obesity caused by bad dietary habits and obesity caused by genetic factors, andimproves the obesity-related symptoms such as fatty liver.

The invention discloses a feed additive for freshwater fish. The feed additive is prepared by extracting platycarya strobilacea infructescence. The additive is applied to freshwater fish culture according to the addition amount of 100-10000 g/t, so that the growth of freshwater fish can be remarkably promoted, the feed coefficient is reduced, the fatness and the serum superoxide dismutase activityare improved, the content of malondialdehyde and nitric oxide in serum is reduced, and the superoxide anion and glutamic oxalacetic transaminase resisting activity is improved. Not only is productionperformance improved, but also fish meat quality is improved. The feed additive does not contain antibiotics, is healthy and environment-friendly, is low in production cost and has a great application prospect.

The invention discloses a method and feed for estimating the optimal energy-protein ratio, and the method comprises the following steps: (1) taking common feed raw material corn-soybean meal as basic ration, and blending bran and soybean oil into compound feed with different metabolic energy AME levels; (2) crushing and uniformly mixing all the raw materials, adding 5% of water, and granulating for later use; (3) adopting a single-factor complete random test design, and selecting healthy test ducks for feeding; (4) calculating the production performance in the feeding stage; at the end of the test, at least one duck with the weight close to the average weight is selected for a slaughtering test every time, and the slaughtering performance is measured; plasma is collected, and glutamic-pyruvic transaminase AST and glutamic oxalacetic transaminase AST are measured. And (5) calculating the optimal energy protein ratio according to a linear broken line regression model (y = l + u * (r-x)). According to the method, the optimal energy-protein ratio is estimated by establishing the regression model of the energy-protein ratio, the production performance and the slaughter performance, the result is more accurate, the application value is higher, and efficient utilization of feed resources is achieved.

The invention relates to a red-increasing and growth-promoting additive for parrot fish. The additive comprises carophyll red and vitamin E at the weight ratio of (7-15):(3-10). According to the invention, carophyll red and vitamin E which are adopted as raw materials are mixed into common feed at the ratio, and then the feed is conventionally used for feeding. Experiments prove that the surface of the parrot fish is obviously colored after the use of the additive, and the coloring effect is far greater than that of a control group; activities of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase are not influenced so that no side influences occur to liver-pancreas of the parrot fish; moreover, the weight increment of the parrot fish and the activities of antioxidant indexes in the liver-pancreas are obviously influenced; in conclusion, the additive can effectively increase the color of the surface of the parrot fish and promote the growth of the parrot fish and has good effect in the increment of the antioxidant ability of the parrot fish and the accumulation of carotenoid.

The invention discloses application of alanyl-glutamine (Ala-Gln) in preparation of a medicine for preventing and treating acute liver failure. The application is characterized in that the alanyl-glutamine or pharmaceutically acceptable salt, ester and solvate thereof is applied to prevention and treatment of an acute immune mouse liver failure model induced by Lipopolysaccharide (LPS) combined with D-galactosamine (D-Gal). Pharmacological experiments find that the alanyl-glutamine administration can obviously improve the liver tissue structure disorder, reduce extravasated blood and edema of liver tissues, reduce glutamic-pyruvic transaminase, glutamic oxalacetic transaminase and other liver function indexes and inhibit inflammatory reactions in the liver. The application has the advantage that the alanyl-glutamine provides a new method for preventing and treating LPS/D-Gal induced acute liver failure and liver injury.

The embodiment of the invention provides a blood transfusion prediction method, system and device in the liver transplantation process and a medium, and belongs to the technical field of medical care information. The method specifically comprises the steps: training an XGBOOST algorithm through a sample data set, and establishing a prediction model; collecting a key information data set of a target person, wherein the key information data set comprises age, portal hypertension, activated partial thrombin time, direct bilirubin content, globulin content, hemoglobin content, glutamic oxalacetic transaminase content, glutamic-pyruvic transaminase content and liver diagnosis information; and inputting the key information data set into the prediction model to obtain a predicted blood transfusion scheme. According to the scheme, the machine learning algorithm is used for learning the sample data set, the prediction model is established, then the collected key information data set of the target person is input into the prediction model, the predicted blood transfusion scheme is obtained, prediction efficiency and precision are improved, and the safety in the operation process is improved.

The invention relates to application of a serum amyloid protein A inhibitor in preparing a medicine for treating acute liver injury, acute liver failure or acute-on-chronic liver failure. The serum amyloid protein A inhibitor is used for blocking SAA1/2, so that the APAP-induced liver injury degree can be remarkably reduced, the repair process after injury can be enhanced, and the level of glutamic-pyruvic transaminase (ALT) and/or glutamic oxalacetic transaminase (AST) in blood can be reduced; the effect of inhibiting SAA1/2 can reduce intrahepatic hemorrhage induced by APAP and aggregation of platelets in the liver. Therefore, the serum amyloid protein A inhibitor can be applied to preparation of medicines for treating acute liver injury, acute liver failure or acute-on-chronic liver failure; a new strategy is provided for treatment of acute liver injury, acute liver failure or acute-on-chronic liver failure, the strategy can make up for the defects that in the prior art, an NAC treatment method is short in window period and large in side effect, and a liver transplantation method is short in donor, immunological rejection and the like to a certain extent, and the method has thecharacteristics of low immunogenicity, low cost and the like.